Skip to main content

Advertisement

Risk of latent tuberculosis in at-risk children with rheumatic diseases

Article metrics

Background

The risk of developing latent TB infection (LTBI) following exposure to active tuberculosis (TB) in children with rheumatic diseases on immunosuppressive therapy is not well established.

Aim

To determine the risk of developing LTBI in children with rheumatic diseases following inadvertent exposure to active TB in the course of their clinical care.

Methods

Data from TB screening by tuberculin skin test (TST) and interferon gamma release assay (Quantiferon TB Gold In tube, (IGRA)) involving at-risk children with rheumatic disease was reviewed. Exposed patients were considered to be at moderate risk of LTBI if they were under 5 years of age, or receiving conventional DMARDs or corticosteroids > 0.5 mg/kg/day, and at high risk if they were receiving biologic DMARDS. High risk patients also had chest X-rays.

Results

Results from 55 children were analyzed; 13 (23.6%) in the high risk category and 42 (76.4%) in the moderate risk category. The duration of exposure to the index case ranged from 30 to 120 minutes. Two children in the high risk group on Etanercept tested positive for TST (negative IGRA). All patients tested negative for IGRA. A positive test result did not correlate with the degree of immunosuppression or cumulative exposure. No patients had symptoms or signs suggestive of active TB and all chest radiographs were normal.

Conclusion

The risk of testing positive for LTBI was low in this cohort of children, even in those on potent immunosuppressants. The sensitivity of TST and IGRA in this situation remains unknown.

Author information

Correspondence to SC Lim.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Keywords

  • Etanercept
  • Rheumatic Disease
  • Risk Category
  • Tuberculin Skin Test
  • Interferon Gamma